{"id":"https://openalex.org/W2884577329","doi":"https://doi.org/10.1002/cpt.1193","title":"Adverse Events Associated With PCSK 9 Inhibitors: A Real\u2010World Experience","display_name":"Adverse Events Associated With PCSK 9 Inhibitors: A Real\u2010World Experience","alternate_titles":[],"publication_year":2018,"publication_date":"2018-07-27","ids":{"openalex":"https://openalex.org/W2884577329","doi":"https://doi.org/10.1002/cpt.1193","mag":"2884577329","pmid":"https://pubmed.ncbi.nlm.nih.gov/30053327","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/6704355"},"language":"en","primary_location":{"id":"doi:10.1002/cpt.1193","doi":"https://doi.org/10.1002/cpt.1193","is_oa":true,"landing_page_url":"https://doi.org/10.1002/cpt.1193","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cpt.1193","source":{"id":"https://openalex.org/S159852663","display_name":"Clinical Pharmacology & Therapeutics","issn_l":"0009-9236","issn":["0009-9236","1085-8733","1532-6535"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Pharmacology &amp; Therapeutics","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2884577329"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cpt.1193","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5007641904","display_name":"Muhammed T. G\u00fcrg\u00f6ze","orcid":"https://orcid.org/0000-0003-0011-3841","observed_orcids":["https://orcid.org/0000-0003-0011-3841"]},"institutions":[{"id":"https://openalex.org/I2801952686","display_name":"Erasmus MC","ror":"https://ror.org/018906e22","country_code":"NL","type":"healthcare","lineage":["https://openalex.org/I2801952686"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"Muhammed T. G\u00fcrg\u00f6ze","raw_affiliation_strings":["Erasmus MC, University Medical Centre Rotterdam, Department of Cardiology, Rotterdam, The Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Erasmus MC, University Medical Centre Rotterdam, Department of Cardiology, Rotterdam, The Netherlands","institution_ids":["https://openalex.org/I2801952686"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5021727663","display_name":"A H G Muller-Hansma","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210139651","display_name":"Netherlands Pharmacovigilance Centre Lareb","ror":"https://ror.org/04fp8ns78","country_code":"NL","type":"facility","lineage":["https://openalex.org/I4210139651"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"Annemarie H.G. Muller\u2010Hansma","raw_affiliation_strings":["Netherlands Pharmacovigilance Centre Lareb, 's-Hertogenbosch, The Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Netherlands Pharmacovigilance Centre Lareb, 's-Hertogenbosch, The Netherlands","institution_ids":["https://openalex.org/I4210139651"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5078141176","display_name":"Michelle M. Schreuder","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2801952686","display_name":"Erasmus MC","ror":"https://ror.org/018906e22","country_code":"NL","type":"healthcare","lineage":["https://openalex.org/I2801952686"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"Michelle M. Schreuder","raw_affiliation_strings":["Erasmus MC, University Medical Centre Rotterdam, Department of Internal Medicine, Rotterdam, The Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Erasmus MC, University Medical Centre Rotterdam, Department of Internal Medicine, Rotterdam, The Netherlands","institution_ids":["https://openalex.org/I2801952686"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112489875","display_name":"Annette M.H. Galema\u2010Boers","orcid":"https://orcid.org/0000-0001-8754-4673","observed_orcids":["https://orcid.org/0000-0001-8754-4673"]},"institutions":[{"id":"https://openalex.org/I2801952686","display_name":"Erasmus MC","ror":"https://ror.org/018906e22","country_code":"NL","type":"healthcare","lineage":["https://openalex.org/I2801952686"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"Annette M.H. Galema\u2010Boers","raw_affiliation_strings":["Erasmus MC, University Medical Centre Rotterdam, Department of Internal Medicine, Rotterdam, The Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Erasmus MC, University Medical Centre Rotterdam, Department of Internal Medicine, Rotterdam, The Netherlands","institution_ids":["https://openalex.org/I2801952686"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088988397","display_name":"Eric H. Boersma","orcid":"https://orcid.org/0000-0002-2559-7128","observed_orcids":["https://orcid.org/0000-0002-2559-7128"]},"institutions":[{"id":"https://openalex.org/I2801952686","display_name":"Erasmus MC","ror":"https://ror.org/018906e22","country_code":"NL","type":"healthcare","lineage":["https://openalex.org/I2801952686"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"Eric Boersma","raw_affiliation_strings":["Erasmus MC, University Medical Centre Rotterdam, Department of Cardiology, Rotterdam, The Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Erasmus MC, University Medical Centre Rotterdam, Department of Cardiology, Rotterdam, The Netherlands","institution_ids":["https://openalex.org/I2801952686"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5036018606","display_name":"Jeanine E. Roeters van Lennep","orcid":"https://orcid.org/0000-0001-6870-9962","observed_orcids":["https://orcid.org/0000-0001-6870-9962"]},"institutions":[{"id":"https://openalex.org/I2801952686","display_name":"Erasmus MC","ror":"https://ror.org/018906e22","country_code":"NL","type":"healthcare","lineage":["https://openalex.org/I2801952686"]}],"countries":["NL"],"is_corresponding":true,"raw_author_name":"Jeanine E. Roeters van Lennep","raw_affiliation_strings":["Erasmus MC, University Medical Centre Rotterdam, Department of Internal Medicine, Rotterdam, The Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Erasmus MC, University Medical Centre Rotterdam, Department of Internal Medicine, Rotterdam, The Netherlands","institution_ids":["https://openalex.org/I2801952686"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5036018606"],"corresponding_institution_ids":["https://openalex.org/I2801952686"],"apc_list":{"value":4410,"currency":"USD","value_usd":4410},"apc_paid":{"value":4410,"currency":"USD","value_usd":4410},"fwci":4.6981,"has_fulltext":true,"cited_by_count":98,"citation_normalized_percentile":{"value":0.95870333,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":93,"max":100},"biblio":{"volume":"105","issue":"2","first_page":"496","last_page":"504"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10394","display_name":"Lipoproteins and Cardiovascular Health","score":0.5121999979019165,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10394","display_name":"Lipoproteins and Cardiovascular Health","score":0.5121999979019165,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11943","display_name":"Pharmacovigilance and Adverse Drug Reactions","score":0.4713999927043915,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12255","display_name":"Biosimilars and Bioanalytical Methods","score":0.0013000000035390258,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/pcsk9-inhibitors","display_name":"PCSK9 inhibitors","score":1.0},{"id":"https://openalex.org/keywords/evolocumab","display_name":"evolocumab","score":0.9909999966621399},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.8960000276565552},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.9309999942779541},{"id":"https://openalex.org/keywords/real-world-data","display_name":"real-world data","score":0.7419999837875366},{"id":"https://openalex.org/keywords/pharmacovigilance","display_name":"pharmacovigilance","score":0.9449999928474426},{"id":"https://openalex.org/keywords/injection-site-reactions","display_name":"injection site reactions","score":0.9639999866485596},{"id":"https://openalex.org/keywords/influenza-like-illness","display_name":"influenza-like illness","score":0.9700000286102295},{"id":"https://openalex.org/keywords/myalgia","display_name":"myalgia","score":0.9940000176429749},{"id":"https://openalex.org/keywords/treatment-discontinuation","display_name":"treatment discontinuation","score":0.7620000243186951},{"id":"https://openalex.org/keywords/ldl-cholesterol-lowering","display_name":"LDL cholesterol lowering","score":0.6290000081062317}],"concepts":[{"id":"https://openalex.org/C2780902209","wikidata":"https://www.wikidata.org/wiki/Q4726914","display_name":"Alirocumab","level":5,"score":0.8209623098373413},{"id":"https://openalex.org/C2778114629","wikidata":"https://www.wikidata.org/wiki/Q15623825","display_name":"Evolocumab","level":5,"score":0.7673394680023193},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7646368145942688},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.6811153888702393},{"id":"https://openalex.org/C2780948078","wikidata":"https://www.wikidata.org/wiki/Q21130010","display_name":"PCSK9","level":5,"score":0.6798854470252991},{"id":"https://openalex.org/C2778616394","wikidata":"https://www.wikidata.org/wiki/Q474959","display_name":"myalgia","level":2,"score":0.6603182554244995},{"id":"https://openalex.org/C57658597","wikidata":"https://www.wikidata.org/wiki/Q1550789","display_name":"Pharmacovigilance","level":3,"score":0.5556322932243347},{"id":"https://openalex.org/C197636746","wikidata":"https://www.wikidata.org/wiki/Q7234359","display_name":"Postmarketing surveillance","level":3,"score":0.5488848686218262},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5402573943138123},{"id":"https://openalex.org/C2778849439","wikidata":"https://www.wikidata.org/wiki/Q6397985","display_name":"Kexin","level":5,"score":0.5391889214515686},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.5036506056785583},{"id":"https://openalex.org/C3020493868","wikidata":"https://www.wikidata.org/wiki/Q55631277","display_name":"Real world data","level":2,"score":0.45483866333961487},{"id":"https://openalex.org/C67761136","wikidata":"https://www.wikidata.org/wiki/Q2105849","display_name":"Post-hoc analysis","level":2,"score":0.4543510973453522},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.4479696452617645},{"id":"https://openalex.org/C187960798","wikidata":"https://www.wikidata.org/wiki/Q7631152","display_name":"Subgroup analysis","level":3,"score":0.41055870056152344},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3448917269706726},{"id":"https://openalex.org/C95190672","wikidata":"https://www.wikidata.org/wiki/Q815382","display_name":"Meta-analysis","level":2,"score":0.12180975079536438},{"id":"https://openalex.org/C2778163477","wikidata":"https://www.wikidata.org/wiki/Q43656","display_name":"Cholesterol","level":2,"score":0.07221707701683044},{"id":"https://openalex.org/C2780745583","wikidata":"https://www.wikidata.org/wiki/Q1316030","display_name":"Apolipoprotein A1","level":4,"score":0.0},{"id":"https://openalex.org/C62746215","wikidata":"https://www.wikidata.org/wiki/Q14890615","display_name":"Apolipoprotein B","level":3,"score":0.0},{"id":"https://openalex.org/C2522767166","wikidata":"https://www.wikidata.org/wiki/Q2374463","display_name":"Data science","level":1,"score":0.0},{"id":"https://openalex.org/C2780072125","wikidata":"https://www.wikidata.org/wiki/Q28350","display_name":"Lipoprotein","level":3,"score":0.0},{"id":"https://openalex.org/C43554185","wikidata":"https://www.wikidata.org/wiki/Q425649","display_name":"LDL receptor","level":4,"score":0.0},{"id":"https://openalex.org/C41008148","wikidata":"https://www.wikidata.org/wiki/Q21198","display_name":"Computer science","level":0,"score":0.0}],"mesh":[{"descriptor_ui":"D000071449","descriptor_name":"Proprotein Convertase 9","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000091362","descriptor_name":"PCSK9 Inhibitors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D000293","descriptor_name":"Adolescent","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000369","descriptor_name":"Aged, 80 and over","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000924","descriptor_name":"Anticholesteremic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D002648","descriptor_name":"Child","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002675","descriptor_name":"Child, Preschool","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004791","descriptor_name":"Enzyme Inhibitors","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007223","descriptor_name":"Infant","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007231","descriptor_name":"Infant, Newborn","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012042","descriptor_name":"Registries","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012307","descriptor_name":"Risk Factors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016208","descriptor_name":"Databases, Factual","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D055815","descriptor_name":"Young Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D060735","descriptor_name":"Pharmacovigilance","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D063806","descriptor_name":"Myalgia","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":false},{"descriptor_ui":"D063806","descriptor_name":"Myalgia","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":false}],"locations_count":5,"locations":[{"id":"doi:10.1002/cpt.1193","doi":"https://doi.org/10.1002/cpt.1193","is_oa":true,"landing_page_url":"https://doi.org/10.1002/cpt.1193","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cpt.1193","source":{"id":"https://openalex.org/S159852663","display_name":"Clinical Pharmacology & Therapeutics","issn_l":"0009-9236","issn":["0009-9236","1085-8733","1532-6535"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Pharmacology &amp; Therapeutics","raw_type":"journal-article"},{"id":"pmid:30053327","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/30053327","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical pharmacology and therapeutics","raw_type":"Journal Article"},{"id":"pmh:oai:pubmedcentral.nih.gov:6704355","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC6704355/","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clin Pharmacol Ther","raw_type":"Text"},{"id":"pmh:oai:pure.eur.nl:openaire/c5ab2e47-a506-4054-b204-25c767a6b36f","doi":null,"is_oa":true,"landing_page_url":"https://pure.eur.nl/en/publications/c5ab2e47-a506-4054-b204-25c767a6b36f","pdf_url":null,"source":{"id":"https://openalex.org/S4306401266","display_name":"EUR Research Repository (Erasmus University Rotterdam)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I913958620","host_organization_name":"Erasmus University Rotterdam","host_organization_lineage":["https://openalex.org/I913958620"],"host_organization_lineage_names":[],"type":"repository"},"license":"other-oa","license_id":"https://openalex.org/licenses/other-oa","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"G\u00fcrg\u00f6ze, M, Muller-Hansma, AHG, Schreuder, M, Boers, JMH, Boersma, E & Roeters van Lennep, J 2019, 'Adverse Events Associated With PCSK9 Inhibitors: A Real-World Experience', Clinical Pharmacology & Therapeutics, vol. 105, no. 2, pp. 496-504. https://doi.org/10.1002/cpt.1193","raw_type":"info:eu-repo/semantics/article"},{"id":"pmh:eur:oai:pure.eur.nl:publications/c5ab2e47-a506-4054-b204-25c767a6b36f","doi":null,"is_oa":false,"landing_page_url":"https://pure.eur.nl/en/publications/c5ab2e47-a506-4054-b204-25c767a6b36f","pdf_url":null,"source":{"id":"https://openalex.org/S4306401266","display_name":"EUR Research Repository (Erasmus University Rotterdam)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I913958620","host_organization_name":"Erasmus University Rotterdam","host_organization_lineage":["https://openalex.org/I913958620"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Clinical Pharmacology &amp; Therapeutics, 105(2), 496 - 504. Wiley-Blackwell","raw_type":"info:eu-repo/semantics/article"}],"best_oa_location":{"id":"doi:10.1002/cpt.1193","doi":"https://doi.org/10.1002/cpt.1193","is_oa":true,"landing_page_url":"https://doi.org/10.1002/cpt.1193","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cpt.1193","source":{"id":"https://openalex.org/S159852663","display_name":"Clinical Pharmacology & Therapeutics","issn_l":"0009-9236","issn":["0009-9236","1085-8733","1532-6535"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Pharmacology &amp; Therapeutics","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[{"id":"https://openalex.org/study-designs/observational-study","display_name":"Observational Study"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320307105","display_name":"Amgen","ror":"https://ror.org/03g03ge92"},{"id":"https://openalex.org/F4320307781","display_name":"Sanofi","ror":"https://ror.org/027vj4x92"},{"id":"https://openalex.org/F4320318070","display_name":"Amryt Pharma","ror":"https://ror.org/02nph9e73"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2884577329.pdf","grobid_xml":"https://content.openalex.org/works/W2884577329.grobid-xml"},"referenced_works_count":35,"referenced_works":["https://openalex.org/W1497552522","https://openalex.org/W1520609538","https://openalex.org/W1890541571","https://openalex.org/W1898803325","https://openalex.org/W2001328643","https://openalex.org/W2005330460","https://openalex.org/W2032160423","https://openalex.org/W2040612932","https://openalex.org/W2048059304","https://openalex.org/W2090909991","https://openalex.org/W2129809363","https://openalex.org/W2152615674","https://openalex.org/W2156363246","https://openalex.org/W2175943040","https://openalex.org/W2247997571","https://openalex.org/W2340257704","https://openalex.org/W2504751597","https://openalex.org/W2520424058","https://openalex.org/W2568987715","https://openalex.org/W2582372330","https://openalex.org/W2594072057","https://openalex.org/W2594441236","https://openalex.org/W2595169180","https://openalex.org/W2596179513","https://openalex.org/W2618303337","https://openalex.org/W2736442303","https://openalex.org/W2746224452","https://openalex.org/W2748800769","https://openalex.org/W2762069281","https://openalex.org/W2765432372","https://openalex.org/W2766232664","https://openalex.org/W2768968665","https://openalex.org/W2770626913","https://openalex.org/W2773258653","https://openalex.org/W4206107200"],"related_works":["https://openalex.org/W4285076932","https://openalex.org/W4309842527","https://openalex.org/W4407136420","https://openalex.org/W4400245691","https://openalex.org/W4406826534","https://openalex.org/W4313490198","https://openalex.org/W4229023932","https://openalex.org/W4410197268","https://openalex.org/W4312489989","https://openalex.org/W4293579034"],"abstract_inverted_index":{"In":[0,61,136],"randomized":[1],"clinical":[2,57],"trials":[3],"(RCTs)":[4],"proprotein":[5],"convertase":[6],"subtilisin/kexin":[7],"9":[8],"(PCSK9)":[9],"inhibitors":[10,51,141],"showed":[11],"a":[12,27,137],"favorable":[13],"safety":[14,148],"profile,":[15],"however,":[16],"\"real-world\"":[17],"data":[18],"on":[19],"adverse":[20],"events":[21],"(AEs)":[22],"is":[23],"scarce.":[24],"Three":[25],"datasets,":[26],"hospital":[28,63],"registry":[29],"(n":[30,38,43],"=":[31,39,44],"164),":[32],"and":[33,41,77,95,101],"two":[34],"Pharmacovigilance":[35],"databases,":[36],"Lareb":[37,94],"149)":[40],"VigiLyze":[42,96],"15,554),":[45],"reporting":[46],"AEs":[47,130],"attributed":[48],"to":[49,151],"PCSK9":[50,85,140],"(alirocumab":[52],"or":[53,110],"evolocumab)":[54],"prescribed":[55],"in":[56,92,108,132],"practice":[58],"were":[59,113],"analyzed.":[60],"the":[62,67,93],"registry,":[64],"41.5%":[65],"of":[66,118,125],"patients":[68,82,119,134],"reported":[69,91],"any":[70],"AE,":[71],"most":[72,133],"often":[73],"injection-site":[74],"reactions":[75],"(33.8%)":[76],"influenza-like":[78],"illness":[79],"(27.9%).":[80],"Twelve":[81],"(7%)":[83],"discontinued":[84],"inhibitor":[86],"treatment.":[87],"Most":[88],"common":[89],"AE":[90],"database":[97],"was":[98],"myalgia":[99],"(12.8%":[100],"8.3%,":[102],"respectively).":[103],"No":[104,115],"clinically":[105],"relevant":[106],"differences":[107],"gender":[109],"between":[111],"drugs":[112],"observed.":[114],"specific":[116],"subgroup":[117],"could":[120],"be":[121],"identified":[122],"at":[123],"risk":[124],"developing":[126],"AEs.":[127],"During":[128],"follow-up,":[129],"resolved":[131],"(71.1%).":[135],"real-world":[138],"setting,":[139],"are":[142],"well":[143],"tolerated":[144],"with":[145],"an":[146],"overall":[147],"profile":[149],"comparable":[150],"RCTs.":[152]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2884577329","counts_by_year":[{"year":2026,"cited_by_count":16},{"year":2025,"cited_by_count":11},{"year":2024,"cited_by_count":20},{"year":2023,"cited_by_count":9},{"year":2022,"cited_by_count":13},{"year":2021,"cited_by_count":11},{"year":2020,"cited_by_count":9},{"year":2019,"cited_by_count":7},{"year":2017,"cited_by_count":2}],"updated_date":"2026-11-16T12:05:36.265796","created_date":"2018-08-03T00:00:00"}
